ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 10.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,400 shares of the company’s stock after buying an additional 1,500 shares during the period. J.W. Cole Advisors Inc.’s holdings in ARS Pharmaceuticals were worth $131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in ARS Pharmaceuticals in the 1st quarter worth $60,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock worth $63,000 after purchasing an additional 4,472 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of ARS Pharmaceuticals during the first quarter worth about $103,000. Principal Financial Group Inc. purchased a new stake in ARS Pharmaceuticals in the second quarter valued at approximately $87,000. Finally, SG Americas Securities LLC acquired a new position in ARS Pharmaceuticals in the 1st quarter worth approximately $119,000. 68.16% of the stock is currently owned by institutional investors and hedge funds.

ARS Pharmaceuticals Stock Performance

SPRY stock opened at $14.86 on Friday. ARS Pharmaceuticals, Inc. has a one year low of $2.55 and a one year high of $16.50. The firm’s fifty day moving average is $11.88 and its 200 day moving average is $9.97.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, research analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Insider Transactions at ARS Pharmaceuticals

In related news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $9.62, for a total value of $962,000.00. Following the sale, the insider now owns 1,496,494 shares of the company’s stock, valued at approximately $14,396,272.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $9.62, for a total value of $962,000.00. Following the sale, the insider now owns 1,496,494 shares in the company, valued at $14,396,272.28. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the sale, the insider now directly owns 5,693 shares of the company’s stock, valued at approximately $79,702. The disclosure for this sale can be found here. Insiders sold a total of 1,043,395 shares of company stock valued at $13,650,032 in the last three months. 40.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on SPRY shares. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Monday. Leerink Partners increased their price target on ARS Pharmaceuticals from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Finally, William Blair raised ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $22.75.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.